Incyte's blood cancer drug Monjuvi, when used in combination with Bristol Myers Squibb's Revlimid and the standard chemotherapy regimen R-CHOP, has shown a 25% reduction in the risk of disease progression, relapse, or death for patients with diffuse large B-cell lymphoma (DLBCL). However, this combination therapy is associated with a higher incidence of severe side effects, with nearly 87% of patients experiencing adverse events compared to 76% in those receiving R-CHOP alone. Additionally, 25.7% of patients on the Monjuvi regimen discontinued treatment due to adverse events, compared to 18% for standard care. The overall death rate was lower in the Monjuvi group at 18.5%, compared to 21.7% for R-CHOP. Incyte's research chief, Pablo Cagnoni, indicated that more comprehensive survival data will be available later. The company is also looking to expand the approval of this therapy for newly diagnosed patients, potentially doubling the eligible population for treatment.